QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on INM-405 Development

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced preclinical results in the development of INM-405 for the treatment of pain. Notably, results from the company’s studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects. InMed suggests that this lack of side effects may position cannabinoid-based compounds as more desirable treatment options than existing systemic pain-relief administration. News of these findings follows the company’s recent filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which marked an important step in InMed’s efforts to protect its intellectual and commercial property.

To view the full press release, visit http://dtn.fm/wY5MD

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.